Ultragenyx to Host Conference Call for Second Quarter 2021 Financial Results and Corporate Update
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will host a conference call on August 2, 2021, at 5 PM ET to discuss its financial results for Q2 2021, ending June 30. The company is known for developing therapies for serious rare genetic diseases and has a diverse portfolio aimed at unmet medical needs. Interested participants can access the live webcast through their website or dial in by phone. This update underscores the company's commitment to efficient drug development and patient care in the rare disease sector.
- Ultragenyx hosts a conference call to discuss Q2 2021 financial results, indicating active engagement with investors.
- Company focused on novel therapies for serious rare genetic diseases, showcasing dedication to addressing unmet medical needs.
- None.
NOVATO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Monday, August 2, 2021 at 5pm ET to discuss its financial results and corporate update for the quarter ended June 30, 2021.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. To participate in the live call by phone, dial (855) 797-6910 (USA) or (262) 912-6260 (International) and enter the passcode 3654725. The replay of the call will be available for one year.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com
Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-475-6370
FAQ
What is the date of Ultragenyx's Q2 2021 earnings call?
Where can I listen to the Ultragenyx Q2 2021 earnings call?
What is Ultragenyx Pharmaceutical known for?
What is the stock symbol for Ultragenyx Pharmaceutical?
